IT / EN

Congenital Muscular Dystrophies

Congenital Muscular Dystrophies (CMDs) are a heterogeneous group of hereditary myopathies characterized by reduced muscle tone and muscle weakness present at birth or within the first few months of life. The infant typically appears “limp” or “floppy,” a condition clinically referred to as “floppy baby syndrome.”

These are rare diseases with an estimated prevalence of 1:100,000 to 1:500,000 live births, and they are primarily classified based on the specific defective muscle protein.

CMDs typically involve multisystemic complications (affecting the brain, eyes, heart, and respiratory system). The clinical progression can vary significantly:

Static or slowly progressive forms: Relatively stable over time.
Rapidly progressive forms: Characterized by a faster decline that can reduce life expectancy.

CMDs are caused by mutations in various genes encoding structural muscle proteins. These protein defects compromise the structural integrity of the muscle fiber and its connection to the surrounding support tissue (extracellular matrix), making the muscle fragile and less efficient.

The inheritance pattern is predominantly autosomal recessive (the affected individual receives one copy of the mutated gene from the father and the other from the mother, who are defined as “healthy carriers”).

The main groups include:

Merosin deficiency (LAMA2 gene)
Collagen VI deficiency (COL6A1, COL6A2, COL6A3 genes)
Dystroglycanopathies (with over 20 genes involved in the $\alpha$ -dystroglycan glycosylation pathway, such as POMT1, POMT2, FKTN, and FKRP).

Ecco la traduzione professionale in inglese per la descrizione clinica delle CMD:

Clinical Manifestations

Clinical presentations vary depending on the genetic subtype, but they share several common features:

Typical Neonatal Signs:

Reduced muscle tone (Hypotonia) at birth (“floppy baby syndrome”)
Feeding difficulties (weak suckling, impaired swallowing)
Neonatal respiratory failure
Delayed motor milestones (e.g., sitting, crawling, walking, etc.)
Early joint contractures (joint stiffness)

Specific Clinical Subgroups

Merosin Deficiency (LAMA2-CMD)

Complete form: Severe hypotonia, early respiratory distress, inability to achieve independent sitting, brain white matter abnormalities (leukodystrophy), and epilepsy (20-30%).
Partial form: Moderate hypotonia and muscle weakness; motor development is delayed, but the prognosis is typically more favorable.

Collagen VI Deficiency

Distal joint hyperlaxity (hands, feet) combined with proximal stiffness (shoulders, hips).
Early contractures of the hips, knees, and elbows.
Skin abnormalities: Fragile skin, keloids (excessive scarring), and prominent hair follicles (follicular hyperkeratosis).
Progressive respiratory failure.

Dystroglycanopathies

This group presents a very broad clinical spectrum:

Severe forms: Neonatal onset often leading to death within the first year of life (Walker-Warburg Syndrome).
Moderate to mild forms: Variable brain involvement (cortical malformations) and ocular anomalies (cataracts, retinal abnormalities), such as Muscle-Eye-Brain disease and Fukuyama Congenital Muscular Dystrophy.

Diagnostic Evaluation
- Neonatal Clinical Assessment: Comprehensive neurological examination, assessment of the degree of hypotonia, and reflex testing.
- Creatine Kinase (CK): Variable elevation (levels are typically normal in Collagen VI defects, but significantly elevated in $\alpha$ -dystroglycanopathies).
- Brain MRI: Used to identify leukodystrophy (common in LAMA2-CMD) or cortical anomalies (typical of $\alpha$ -dystroglycanopathies).
- Muscle MRI: To recognize specific patterns of muscle involvement, the presence of edema, and the degree of fibro-fatty replacement.
- Genetic Testing: NGS (Next Generation Sequencing) panels for CMD-related genes; clinical exome sequencing for negative or uncertain cases.
  
  At our center, the identification of molecular defects in related genes is currently performed using Next-Generation Sequencing (clinical exome), with simultaneous analysis of the primary genes involved, which are then studied and reported via a virtual panel. Variant validation in patients and carrier testing for family members are performed using direct sequencing (Sanger sequencing).
- Muscle Biopsy: Immunohistochemistry for specific proteins (anti-merosin, anti-collagen VI, and anti- $\alpha$ -dystroglycan).
- Specialist Consultations:
  - Cardiology: Echocardiogram.
  - Ophthalmology: Fundus examination (fundus oculi).
  - Respiratory: Spirometry and polysomnography.

Available therapies

Management and Treatment

Currently, there are no approved disease-modifying therapies for CMDs; management is primarily symptomatic and supportive:

Respiratory Management

Ventilatory Support: Non-invasive ventilation (NIV) using CPAP/BiPAP, or invasive ventilation via tracheostomy for the most severe cases.
Respiratory Physiotherapy: Including airway clearance techniques and mechanical cough assistance (e.g., Cough Assist).
Monitoring: Regular oxygen saturation monitoring and arterial blood gas (ABG) analysis.

Nutritional Management

Dysphagia Evaluation: Assessment via FEES (Fiberoptic Endoscopic Evaluation of Swallowing) or videofluoroscopy.
Dietary Adjustments: Modification of food textures, along with caloric and/or vitamin supplementation for milder cases.
Enteral Nutrition: Placement of a PEG (Percutaneous Endoscopic Gastrostomy) tube for patients with severe dysphagia.

Multidisciplinary Rehabilitative Approach

Physiotherapy: Passive mobilization and prevention of joint contractures.
Occupational Therapy: Provision of postural aids and AAC (Augmentative and Alternative Communication).
Orthopedic Management: Use of orthoses (braces) and surgical intervention for severe skeletal deformities (e.g., scoliosis).
Neurological Support: Epilepsy management and cognitive stimulation.

Palliative Care

Symptom control and family support for severe, life-limiting forms.

Research in progress

Ecco la traduzione tecnica riguardante le prospettive di ricerca e le terapie avanzate:

Research and Emerging Therapies

Research in the field of CMD is rapidly evolving, focusing on several innovative strategies:
- Gene Therapy Development: Utilization of AAV (Adeno-Associated Virus) vectors for LAMA2 and Collagen VI related dystrophies.
- Exon-skipping: Targeted therapies for specific mutations designed to bypass defective genetic sequences.
- Cell-based Therapies: Investigation into the use of stem cells and myoblasts to regenerate muscle tissue.
- Pharmacological Modulators: Development of drugs for protein upregulation and anti-fibrotic agents to reduce muscle scarring.
- Genome Editing (CRISPR): Precise correction of genetic mutations at the DNA level.
- Biomarker Identification: Discovery of new biological markers to accurately monitor disease progression and treatment efficacy.
- Cellular Models for Drug Screening: Development of in vitro models (such as patient-derived iPSCs) for high-throughput testing of potential therapeutic compounds.